June 19, 2024
Cypherpunk meets bluegrass: how Justin Holmes is transforming traditional music funding and distribution with blockchain

“The best report Benzinga has ever produced”

Huge returns are possible in this market! For a limited time, get access to Benzinga Insider reports, normally $47/month, for just $0.99! Discover wildly undervalued stocks before they skyrocket! Time is Running Out! Act fast and secure your future property at this incredible discount! Claim your $0.99 offer now!

advertising related

Quantum-C Incorporated (NASDAQ:QSI) (“Quantum-C,” “QSI” or the “Company”), the protein sequencing company™, today announced the acquisition of Immunicom, Inc. Announced the appointment of Amir Jafri as President and CEO. Its board of directors.

This press release features multimedia. Watch the full release here:

Enter to Win $500 in Stocks or Crypto

Enter your email and you’ll get Benzinga’s last Morning Update, a free $30 gift card, and more!

“Amir’s leadership track record speaks for itself,” said Jeff Hawkins, CEO of Quantum-C. “He has successfully managed businesses across multiple industries and built and led world-class R&D organizations responsible for the advanced technology development and launch of over 50 products and technologies globally. His experience with product development and “His focus on operational rigor will be an asset as we continue to expand the company and break new ground in proteomics research.”

Mr. Jafari has over 35 years of experience in biotech, healthcare technology and devices working in Fortune 20 companies and his own startup. In 2013, he founded Immunicom, a medical technology company focused on developing innovative, non-pharmaceutical approaches to treating cancer and inflammatory and autoimmune diseases. Previously, Mr. Jafari held executive leadership positions at West Health, Cardinal Health and Manpower Group. Early in his career, he founded two healthcare startups, which were later acquired. Currently, he serves on the boards of various health care technology startup companies and non-profit organizations. Mr. Jafari is the inventor of over 40 patents covering products and technologies in various industries and applications. Mr. Jafari received a Bachelor of Science degree from Houston Christian University with a double major in Chemistry and Biology and a minor in History.

Mr. Jafari said, “I am excited by Quantum-C’s pioneering work in next-generation protein sequencing, enabling wide-scale access to proteomic data for every scientist, everywhere.” “My experience building and leading businesses that have developed and successfully brought advanced technologies to market positions me well to help guide the company into its next phase of growth.”

About Quantum-C Incorporated

Quantum-C, the Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research to advance drug discovery and diagnostics with DNA sequencing. Has been done Learn more at quantum-si.com.

forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ materially from its expectations, estimates and projections and, as a result, you should not rely on these forward-looking statements as predictions of future events. “Expect,” “estimate,” “project,” “budget,” “forecast,” “estimate,” “intend,” “plan,” “could,” “will,” “could,” “should Words such as “” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations regarding future performance and development and the commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that may cause actual results to differ materially from those discussed in the forward-looking statements. Results may differ from actual results. Most of these factors are beyond the Company’s control and are difficult to predict. Factors that could cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq Stock Market; the ability to recognize the anticipated benefits of the business combination, which may be affected by competition, among other things; and the Company’s ability to profitably manage growth and retain its key employees; our ongoing leadership transition; changes in applicable laws or regulations; the Company’s ability to raise future financing; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any products the Company may introduce in the future; the potential properties and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and the Company’s other products following commercialization; the Company’s ability to obtain and maintain regulatory approval for its products, and the restrictions and limitations related to any approved products; the Company’s ability to identify, license or acquire additional technology; the Company’s ability to maintain its existing leases, licenses, manufacturing and supply agreements; the Company’s ability to compete with other companies that are currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of whom have greater market share than the Company; have financial and marketing resources; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets either alone or in partnership with others once commercialized; the Company’s estimates regarding future expenses, future revenues, capital requirements and additional financing needs; Financial performance of the company; and other risks and uncertainties described under “Risk Factors” in the Company’s annual report for the fiscal year ended December 31, 2022 and the Company’s other filings with the SEC. The Company cautions that the above list of factors is not exclusive. The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company does not undertake or assume any obligation to publicly release any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances. , on which any such statement is based.

“The best report Benzinga has ever produced”

Huge returns are possible in this market! For a limited time, get access to Benzinga Insider reports, normally $47/month, for just $0.99! Discover wildly undervalued stocks before they skyrocket! Time is Running Out! Act fast and secure your future property at this incredible discount! Claim your $0.99 offer now!

advertising related

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Source: www.benzinga.com

Leave a Reply

Your email address will not be published. Required fields are marked *